Form D · Biotechnology
Surebion, Inc.
Los Angeles, CA · CIK 0002083970
Offering snapshot reported Sep 5, 2025 · SEC filing
- Reported sold
- $35 Offering amount: $35
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Aug 21, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 5, 2025 | Initial | $35 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 04, 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-556723
Source: Form D, filed Sep 5, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Troy Barring | Director, Executive |
| Robert Damoiseaux | Director |
| Susanne Nichalas | Director |
| Stephen Paul Rothman | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7938 Reading Avenue
Los Angeles, CA, 90045
Los Angeles, CA, 90045